【摘要】 目的检测造血与淋巴组织肿瘤患者红细胞补体受体1（CR1）分子数量及其基因组密度多态性的变化。方法采集静脉血,用FITC标记的鼠抗人Cd₃₅单抗标记红细胞,应用流式细胞仪测定了24例造血与淋巴组织肿瘤患者、21例健康对照红细胞CR1分子的数量。采用PCR和HindⅢ酶切技术测定红细胞CR1密度相关基因组的多态性。结果造血与淋巴组织肿瘤患者红细胞CR1分子数量平均值为（80.7±13.3）个/红细胞,健康对照的红细胞CR1分子数量平均值为（105.5±8.8）个/红细胞。造血与淋巴组织肿瘤患者与健康对照相比,其红细胞平均CR1分子数量减少,差异有统计学意义（t=7.234,P<0.0001）。造血与淋巴组织肿瘤患者较健康人HH型所占比例降低,HL型所占比例升高,但差异无统计学意义。结论遗传基因的变化可能引起造血与淋巴组织肿瘤患者红细胞CR1分子数量的改变。更多还原

【Abstract】 Objective To detect the number of E-CR1 and study the change regularity of E-CR1 genomic density polymorphism of patients with hematologic and lymphoid neoplasms and that of normal con- trois.Methods Red blood cells from venous blood are labeled by mouse anti-human CD₃₅-FITC monoclonal antibody.Using flow cytometry,we determine the number of ECR1 of 24 patients with hematologic and lym- phoid neoplasms and that of 21 normal controls.Polymerase chain reaction （PCR） and HindⅢrestriction en- zyme digestion were used to detect the change of E-CR1 genomic density polymorphism.Results The mean value of the number of CR1 on each RBC of 24 patients is （80.7±13.3） and that of the normal controls is （105.5±8.8）.Comparing with the controls,ECR1 of the patients with hematologic and lymphoid neoplasms are decreased significantly （t=7.234,P<0.0001）.The E-CR1 genomic density polymorphism distribution state was type HH 76.2 %,HL 14.3%,LL 9.5 %,and that of the patients was HH 58.3 %,HL 29.2 %,LL 12.5 %. The spot mutation rate of ECR1 gene in patients with hematologic and lymphoid neoplasms was higher than that in normal people but has no significant deviation.Conclusion The spot mutation of E-CR1 gene in pa- tients with hematologic and lymphoid neoplasms may be related to the change of the number of E-CR1.更多还原